Skip to content

US · LABT · BIOTECHNOLOGY

Lakewood-Amedex Biotherapeutics, Inc. (LABT) intrinsic value and stock valuation

$1.98as of 2026-09-18 · Mkt cap 3.66M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lakewood-Amedex Biotherapeutics, Inc. DCF and intrinsic value

InvestorsCraft values LABT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LABT’s statements →

Lakewood-Amedex Biotherapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology University Park, FL, US lakewoodamedex.com

How the business is doing

Fiscal 2025–2023, USD

Revenue
$0.00
20252023
Net income
-$-8.28T
20252023
Free cash flow
-$-1.94T
20252025
Total equity
-$-1.96T
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2023, USD
FYFYFY
Revenue$0.00$0.00$0.00
Operating income-$-3.77T-$-4.03T-$-8.64T
Net income-$-3.85T-$-4.86T-$-8.28T
EPSd-$-2.76M-$-6.94M-$-11.84M
Operating cash flow-$-1.94T——
Capital expenditure$0.00——
Free cash flow-$-1.94T——
Total assets$481.6B——
Total debt$1.66T——
Net debt$1.42T——
Total equity-$-1.96T——
Cash and short-term investments$236.4B——
Income statement
FYFYFY
Revenue$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00
Research and development expenses$1.26T$2.1T$5.53T
Selling, general and administrative expenses$2.51T$1.92T$3.1T
Other expenses$4.63B$6.3B$11.6B
Operating expenses$3.77T$4.03T$8.64T
Cost and expenses$3.77T$4.03T$8.64T
Interest income$25.6B$142.6B$360.1B
Interest expense$100.9B$5B$10B
Depreciation and amortization$120B$118.6B$121B
Ebitda-$-3.63T-$-4.73T-$-8.15T
Operating income-$-3.77T-$-4.03T-$-8.64T
Total other income/expenses, net-$-75.27B-$-828.59B$354.8B
Income before tax-$-3.85T-$-4.86T-$-8.28T
Income tax expense$0.00$0.00$0.00
Net income-$-3.85T-$-4.86T-$-8.28T
Weighted average shares outstanding$1.39T$699.5B$699.5B
Weighted average diluted shares outstanding$1.39T$699.5B$699.5B
Balance sheet
FY
Cash and short-term investments$236.4B
Net receivables$0.00
Inventory$0.00
Total current assets$305.4B
Property, plant and equipment, net$168.1B
Goodwill and intangible assets$0.00
Long-term investments$0.00
Total non-current assets$176.2B
Total assets$481.6B
Accounts payable$381B
Short-term debt$1.62T
Deferred revenue$0.00
Total current liabilities$2.41T
Long-term debt$41B
Deferred revenue, non-current$0.00
Total non-current liabilities$41B
Capital lease obligations$160.3B
Total liabilities$2.45T
Common stock$704M
Retained earnings-$-53.35T
Accumulated other comprehensive income (loss)$0.00
Total equity-$-1.96T
Total investments$0.00
Total debt$1.66T
Net debt$1.42T
Cash flow statement
FY
Net income-$-3.85T
Depreciation and amortization$120B
Stock-based compensation$1.35T
Change in working capital$429.5B
Accounts receivable$0.00
Inventory$0.00
Accounts payable$214.6B
Net cash provided by operating activities-$-1.94T
Investments in property, plant and equipment$0.00
Acquisitions, net$0.00
Net cash used for investing activities$0.00
Common stock issued$0.00
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities$1.5T
Net change in cash-$-444.7B
Cash at end of period$236.4B
Operating cash flow-$-1.94T
Capital expenditure$0.00
Free cash flow-$-1.94T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lakewood-Amedex Biotherapeutics, Inc.

        Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

        CEO
        Kelvin Cooper
        Employees
        5
        Beta
        -4.76

        Explore

        Frequently asked questions

        What is the intrinsic value of Lakewood-Amedex Biotherapeutics, Inc. (LABT)?

        InvestorsCraft does not currently publish an intrinsic value for LABT. How the IC value is calculated.

        Is LABT undervalued?

        InvestorsCraft does not publish an undervaluation signal for LABT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.